Vaccines against Human Immunodeficiency Virus -- Progress and Prospects

Publisher Website
Google Scholar
Abstract
The frightening pace of the worldwide spread of the human immunodeficiency virus (HIV) demands that priority be placed on the development of an effective vaccine1. Two distinct populations of viruses responsible for the acquired immunodeficiency syndrome (AIDS) have been defined: HIV type 2 (HIV-2), the viral group responsible for AIDS in West Africa, and HIV type 1 (HIV-1), the viral group that accounts for the AIDS epidemic in Central Africa and the rest of the world2. The genomes of both HIV groups encode for three structural proteins: an envelope glycoprotein that constitutes the viral outer coat, a core . . .